The Asia Pacific Male Infertility Market is expected to witness market growth of 8.9% CAGR during the forecast period (2020-2026).
One of the key causes causing male infertility is sperm heterogeneity of DNA. Male infertility is a heterogeneous group of disorders, known causes account for only 30-50 percent, and unknown cause (idiopathic) is the rest. Infertility affects about 15 percent of people of reproductive age, and the male problem alone involves about 40 percent of the problems.
Tobacco smoke contains approximately 4,000 compounds, like alkaloids, nitrosamines, and inorganic molecules, and some of these are reactive oxygen or nitrogen species. A positive and significant association has been identified between active smoking and sperm DNA fragmentation and also axonemal damage. Smoking is often associated with a decreased sperm count. Smoking is considered to enhance spermatogenesis by increasing the production of norepinephrine, which increases the conversion of testosterone to estrogen causing decreased testosterone levels.
Sperm agglutination refers to the amount of sperm stuck together in the sample given. When evaluating a fertility test result, the percentage assigned to sperm agglutination is the percentage of sperm stuck together in the sample. For example, if the semen sample had only half the sperm sticking together, the report is expected to read only 50 percent sperm agglutination.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
By Tests
By Country
Companies Profiled
Unique Offerings from the Publisher
One of the key causes causing male infertility is sperm heterogeneity of DNA. Male infertility is a heterogeneous group of disorders, known causes account for only 30-50 percent, and unknown cause (idiopathic) is the rest. Infertility affects about 15 percent of people of reproductive age, and the male problem alone involves about 40 percent of the problems.
Tobacco smoke contains approximately 4,000 compounds, like alkaloids, nitrosamines, and inorganic molecules, and some of these are reactive oxygen or nitrogen species. A positive and significant association has been identified between active smoking and sperm DNA fragmentation and also axonemal damage. Smoking is often associated with a decreased sperm count. Smoking is considered to enhance spermatogenesis by increasing the production of norepinephrine, which increases the conversion of testosterone to estrogen causing decreased testosterone levels.
Sperm agglutination refers to the amount of sperm stuck together in the sample given. When evaluating a fertility test result, the percentage assigned to sperm agglutination is the percentage of sperm stuck together in the sample. For example, if the semen sample had only half the sperm sticking together, the report is expected to read only 50 percent sperm agglutination.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Scope of the Study
Market Segmentation:
By Treatment
- Assisted Reproductive Technology & Varicocele Surgery and
- Medication
By Tests
- DNA Fragmentation Technique
- Oxidative Stress Analysis
- Computer Assisted Semen Analysis
- Microscopic Examination
- Sperm Agglutination
- Sperm Penetration Assay and
- Other Tests
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Male Infertility Market by Treatment
Chapter 4. Asia Pacific Male Infertility Market by Test
Chapter 5. Asia Pacific Male Infertility Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Methodology
LOADING...
